Literature DB >> 26083251

The Relation Between the Degree of Left Ventricular Mass Regression and Serum Potassium Level Change in Patients With Primary Aldosteronism After Adrenalectomy.

Che-Wei Liao1, Aaron Chen, Yen-Tin Lin, Yi-Yao Chang, Shuo-Meng Wang, Vin-Cent Wu, Chi-Sheng Hung, Kwan-Dun Wu, Shih-Chieh Chueh, Yen-Hung Lin.   

Abstract

BACKGROUND: Primary aldosteronism (PA) is one of the major etiologies for secondary hypertension featuring more prominent left ventricular hypertrophy. The purpose of the study was to investigate the predictive factors of left ventricular mass index (LVMI) regression in patients with PA after adrenalectomy.
METHODS: We prospectively analyzed 30 patients with aldosterone-producing adenoma (APA) who received adrenalectomy from October 2006 to September 2008. Echocardiography was performed preoperation and 1 year after operation.
RESULTS: Thirty patients with aldosterone-producing adenoma undergoing adrenalectomy were enrolled. In a 1-year follow-up, LVMI decreased significantly by an average of 18.6%. Net LVMI decrease (ΔLVMI) was associated with preoperative LVMI, preoperative serum potassium level, baseline systolic blood pressure (SBP), baseline diastolic blood pressure, net SBP decrease (ΔSBP), net diastolic blood pressure decrease, preoperative/postoperative change of log-transformed plasma aldosterone concentration, preoperative/postoperative change of log-transformed plasma renin activity, and preoperative/postoperative change of serum potassium level (Δserum potassium level). In a multiple regression analysis, preoperative LVMI (β = -0.287, P = 0.049), ΔSBP (β = 0.518, P = 0.01), and Δserum potassium level (β = -20.471, P = 0.014) were significantly correlated with ΔLVMI.
CONCLUSIONS: The LVMI in patients with PA regressed significantly after adrenalectomy. Preoperative LVMI, ΔSBP, and Δserum potassium levels are independent factors associated with the degree of LVMI regression.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26083251     DOI: 10.1097/JIM.0000000000000215

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  5 in total

Review 1.  Left ventricular remodeling and dysfunction in primary aldosteronism.

Authors:  Cheng-Hsuan Tsai; Chien-Ting Pan; Yi-Yao Chang; Zheng-Wei Chen; Vin-Cent Wu; Chi-Sheng Hung; Yen-Hung Lin
Journal:  J Hum Hypertens       Date:  2020-10-16       Impact factor: 3.012

2.  Hemodynamic and Non-Hemodynamic Components of Cardiac Remodeling in Primary Aldosteronism.

Authors:  Chien-Ting Pan; Xue-Ming Wu; Cheng-Hsuan Tsai; Yi-Yao Chang; Zheng-Wei Chen; Chin-Chen Chang; Bo-Ching Lee; Che-Wei Liao; Ya-Li Chen; Lung-Chun Lin; Yi-Ru Chang; Chi-Sheng Hung; Yen-Hung Lin
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-19       Impact factor: 5.555

3.  Comparison of Echocardiographic Changes Between Surgery and Medication Treatment in Patients With Primary Aldosteronism.

Authors:  Tomomi Ueda; Yuya Tsurutani; Jun Osada; Kosuke Inoue; Yoshitomo Hoshino; Masato Ono; Kazuki Nakai; Jun Saito; Kazuhiko Yumoto; Tetsuo Nishikawa
Journal:  J Am Heart Assoc       Date:  2022-06-29       Impact factor: 6.106

4.  Increased myocardial sodium signal intensity in Conn's syndrome detected by 23Na magnetic resonance imaging.

Authors:  Martin Christa; Andreas M Weng; Bettina Geier; Caroline Wörmann; Anne Scheffler; Leane Lehmann; Johannes Oberberger; Bettina J Kraus; Stefanie Hahner; Stefan Störk; Thorsten Klink; Wolfgang R Bauer; Fabian Hammer; Herbert Köstler
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2019-03-01       Impact factor: 6.875

5.  Left Ventricular Dysfunction in Patients With Primary Aldosteronism: A Propensity Score-Matching Follow-Up Study With Tissue Doppler Imaging.

Authors:  Yi-Yao Chang; Che-Wei Liao; Cheng-Hsuan Tsai; Ching-Way Chen; Chien-Ting Pan; Zheng-Wei Chen; Ya-Li Chen; Lung-Chun Lin; Yi-Ru Chang; Vin-Cent Wu; Kwan-Dun Wu; Chi-Sheng Hung; Yen-Hung Lin
Journal:  J Am Heart Assoc       Date:  2019-11-13       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.